Clinical Trial

A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the safety and tolerability of XmAb657 in healthy participants and participants with autoimmune diseases. Participants will be given XmAb657 subcutaneously (SC) by injection under the skin.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2027-02 -> 2028-10 2026-05-23
minor Completion pushed: 2027-02 -> 2028-10 2026-05-23
Trial Details
NCT Number NCT07284797
Lead Sponsor Xencor, Inc.
Conditions Healthy, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, Sjögren's Disease
Enrollment 60 participants
Start Date 2026-02-24
Primary Completion 2028-10 (estimated)
Study Completion 2028-10 (estimated)
Updated on ClinicalTrials.gov 2026-08-03